These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7883776

  • 1. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
    Katz A, Epelman S, Anelli A, Gorender EF, Cruz SM, Oliveira RM, Marques LA.
    J Cancer Res Clin Oncol; 1995; 121(2):128-31. PubMed ID: 7883776
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH, Elias A, Ryan L.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [Abstract] [Full Text] [Related]

  • 3. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
    Manegold C, Drings P, Pawinski A, Lentz MA, van Glabbeke M, van Zandwijk N, Bachmann P, Schnaars Y, Skacel Z, Zatloukal P, Dolensky J, Jackevicius A, Petruzelka L, Giaccone G.
    Ann Oncol; 1996 Aug; 7(6):637-9. PubMed ID: 8879380
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN, Krook JE, Mailliard JA, Hartmann LC, Wieand HS.
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dosing and side-effects of ifosfamide plus mesna.
    Brade WP, Herdrich K, Kachel-Fischer U, Araujo CE.
    J Cancer Res Clin Oncol; 1991 Dec; 117 Suppl 4():S164-86. PubMed ID: 1795007
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P, Rasschaert M, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB.
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J.
    Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
    [Abstract] [Full Text] [Related]

  • 19. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
    Güllü I, Yalçin S, Tekuzman G, Barişta I, Alkiş N, Celik I, Zengin N, Güler N, Kars A, Baltali E.
    Cancer Invest; 1996 May; 14(3):239-42. PubMed ID: 8630686
    [Abstract] [Full Text] [Related]

  • 20. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH, Elias A.
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.